KRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Karuna Therapeutics's total inventories for the quarter that ended in Dec. 2023 was $0.00 Mil. Karuna Therapeutics's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Karuna Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $31.01.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Karuna Therapeutics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karuna Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Total Inventories | Get a 7-Day Free Trial | - | - | - | - | - |
Karuna Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Total Inventories | Get a 7-Day Free Trial | - | - | - | - | - |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Karuna Therapeutics (NAS:KRTX) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Karuna Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is
Net-Net Working Capital Per Share (Q: Dec. 2023 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (1262.813 | + | 0.75 * 0 | + | 0.5 * 0 | - | 81.974 |
- | 0 | - | 0) | / | 38.0775 | ||
= | 31.01 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Karuna Therapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2023 ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Karuna Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Dec. 2023 ) | / | Average Total Inventories (Q: Dec. 2023 ) |
= | 0 | / | 0 | |
= | N/A |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Karuna Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | 0 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Karuna Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephen K. Brannan | officer: Chief Medical Officer | C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110 |
Jason Parker Brown | officer: Chief Financial Officer | KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110 |
Jeffrey M Jonas | director | ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017 |
Troy A. Ignelzi | officer: Chief Financial Officer | C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170 |
Andrew Craig Miller | officer: Chief Operating Officer | C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110 |
Laurie J Olson | director | C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Kane William P Jr | officer: Chief Commercial Officer | C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
William Meury | director, officer: President and CEO | C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
Atul Pande | director | C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
Charmaine Lykins | officer: Chief Commercial Officer | C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110 |
Steven M Paul | director, officer: President & CEO | C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285 |
Puretech Health Llc | 10 percent owner | 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
Denice Torres | director | 3 RABBIT RUN DRIVE, NEW HOPE PA 18938 |
David E. Wheadon | director | C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045 |
From GuruFocus
By GuruFocus Research • 10-11-2023
By Business Wire • 12-22-2023
By Business Wire Business Wire • 05-04-2023
By Business Wire • 08-03-2023
By PRNewswire • 12-22-2023
By Business Wire • 11-29-2023
By Business Wire • 10-19-2023
By Business Wire • 11-01-2023
By PRNewswire • 01-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.